ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
From Germany to the world: analysis of 25,931 documents (from 1873 to 2025) published in Naunyn-Schmiedeberg's Archives of Pharmacology.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A bibliometric study of the most-cited research articles and reviews in Naunyn-Schmiedeberg's Archives of Pharmacology (1969-2024).Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Country-specific citation disparities in Naunyn-Schmiedeberg's Archives of Pharmacology from 2001 to 2024.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Naunyn-Schmiedeberg's Archives of Pharmacology has been a prominent journal in pharmacology since its inception in 1873, contributing significantly to experimental and clinical pharmacology, as well as toxicology. Despite its origins as the official journal of the German Society of Experimental and Clinical Pharmacology and Toxicology, there is a commonly held assumption that it predominantly publishes research from Germany. This study challenges that notion by examining the journal's publication dynamics over time, including the historical output, international participation, and regional contributions. The analysis of 25,931 documents indexed from 1873 to 2025 reveals a significant increase in global engagement, with contributions from 104 countries. While Germany remained the leading contributor until 2020, a decline in its share of publications is observed, with countries like China, India, and Iran surpassing Germany in recent years. The study demonstrates the journal's growing international influence and its evolution into a globally recognized platform for pharmacological research. In parallel with its increasing international reach, the journal has distinguished itself through an active commitment to academic integrity and ethical publishing. Initiatives such as post-publication image reviews, retractions of fraudulent articles, and mandatory AI disclosure policies reflect its proactive stance against scientific misconduct. Furthermore, its support for gender equity and historical accountability-evident in studies on editorial diversity, and award disparities-underscores its role as a pharmacological journal with a conscience. Together, these findings highlight both the geographic diversification and ethical leadership of a journal shaping pharmacological science on a global scale.
Indexed as
Identifiers
40317317What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.